COMMUNIQUÉS West-GlobeNewswire

Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix
19/10/2026
The joint venture between IBA and Framatome will leverage Telix’s capabilities to accelerate the production and availability of Astatine-211 in the US market. Louvain-la-Neuve, Belgium, Paris, France, Indianapolis, [...]
Ekalia franchit une étape importante dans le déploiement de l’astate-211 aux États-Unis grâce à un accord de collaboration avec Telix
19/10/2026
La joint-venture entre IBA et Framatome s’appuiera sur les capacités de Telix afin d’accélérer la production et la disponibilité de l’astate-211 sur le marché américain. Louvain-la-Neuve, Belgique, Paris, France, [...]
OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
19/10/2026
Topline results to be presented by Federico Cappuzzo, MD, PhD, on October 25, 2026, at the Annual Meeting of the European Society for Medical Oncology (ESMO) in Madrid OSE Immunotherapeutics to host a KOL webcast on [...]
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 randomisée Combi-TED de Tedopi® (OSE2101) dans le cancer du poumon non à petites cellules métastatique
19/10/2026
Les résultats de Topline seront présentés par le Pr Federico Cappuzzo, PhD, le 25 octobre 2026 au congrès annuel de l’ European Society for Medical Oncology (ESMO) à Madrid OSE Immunotherapeutics organisera un webcast [...]
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
19/10/2026
Collaboration establishes a framework for a dedicated U.S. source of astatine-211 ( 211 At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT). Secures long-term [...]
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio
19/10/2026
Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer Patient- [...]
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
19/10/2026
Press release – No. 21 / 2026 Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 ZP9830 is a novel Kv1.3 ion channel blocker [...]
JJP Biologics Doses the First Patients in Phase 1b Clinical Trial of Nebaprubart in Rheumatoid Arthritis (RA)
19/10/2026
Expansion of nebaprubart (JJP-1212) into RA follows positive interim data from its ongoing Phase 1b trial in linear IgA dermatosis (LAD), marking the second indication for the Company’s lead asset and expanding clinical [...]
IBA launches NEPTIS® Perform Duo, one synthesizer module from tracer development to routine production
19/10/2026
First new product from ORA, since IBA acquired ORA in December 2025 Louvain-la-Neuve, Belgium – October 19, 2026 7 a.m. – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology [...]
IBA lance NEPTIS® Perform Duo, un module de synthèse unique pour le développement de traceurs et leur production de routine
19/10/2026
Premier nouveau produit lancé par ORA depuis son acquisition par IBA en décembre 2025. Louvain-la-Neuve, Belgique, 19 octobre 2026 à 7h00 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’ [...]
Intelligent Scopes Unveils the ISC 100: The Solution Enabling Urology AI to Work Beside Any Cystoscopy Tower — No Replacement, No Rewiring, No Cloud
19/10/2026
Compact edge platform brings ISC’s AI software to the point of care on NVIDIA Jetson; first software device, CystoSmart™, cleared in Brazil and Singapore ISC 100 by Intelligent Scopes Corp CystoSmart running on the ISC [...]
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
19/10/2026
Presentations to cover updates across Eikon’s clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology- [...]
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
19/10/2026
Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy Data to be presented as a rapid oral presentation at ESMO Congress 2026 on [...]
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
18/10/2026
WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
18/10/2026
WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology [...]
TransCon® CNP (navepegritide), administré une fois par semaine, reçoit un avis favorable du CHMP dans le traitement de l’achondroplasie chez l’enfant
17/10/2026
La décision finale de la Commission européenne est attendue au quatrième trimestre 2026 COPENHAGUE, Danemark, 17 oct. 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq : ASND) a annoncé aujourd’hui que le Comité des [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16/10/2026
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Avicanna Transitions US Listing to OTCQB
16/10/2026
TORONTO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company ) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
16/10/2026
PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor [...]

Pages